Last fall marked the start of a Phase 1 clinical trial at Oklahoma Medical Research Foundation, a culmination of work from its researchers on a compound named OKN-007, which has shown marked success in animal trials. The story behind the drug has the makings of good fiction: a family tragedy, an intrepid optimist and several […]